


Substance Use **Disorders Institute**

EDUCATION • POLICY • RESEARCH



Implementing buprenorphine pharmacotherapy in a large urban jail system, Philadelphia Department of Prisons, 2018-2019

Gail Groves Scott, MPH, University of the Sciences, Philadelphia, PA Bruce Herdman, PhD, Chief of Medical Operations, Philadelphia Department of Prisons, Philadelphia, PA Jon Lepley, DO, CCHP, Corizon Health, Philadelphia, PA

METHODS	
Case study. Interviews, and internal data from program.	Des
BUPRENORPHINE IMPLEMENTATION	Ide
LAUNCHED: Feb. 2018 pilot program for women (1 facility) EXPANDED: Sept. 2018 to other 5 PDP facilities, all men	rec
 Nurse screens all newly incarcerated (within 4 hours of intake) for opioid use disorder (OUD) Opioid withdrawal assessment, inc. urine drug screen Discusses buprenorphine initiation with those who meet criteria & flags chart Nurse can request 4 mg dose if needed for withdrawal symptoms w/verbal order Physician face to face appt- patient assessment within 24 hrs. Patient signs informed consent. RX ordered 	0
Buprenorphine daily observed dosing Day 1 = 4 mg/ day Day 2+ = 8 mg/ day	0
 Daily Protocols for dedicated "med-line" Nurse dispense from med cart. Patient moves to chair, waits while tablet dissolves. Patient has water to moisten mouth, drink after. Correctional officer does mouth check to confirm tablet has dissolved. At program launch: Stock bottle supply + CRUSHED buprenorphine generic monotherapy tablet – in med cup Patient Re-entry: given "bridge" RX for 5 days 	
+ Naloxone kit +Overdose prevention training Formulation change (3/19): buprenorphine/naloxone tablet, individualized blister pack w/15 doses	0 2 2 0 2
Re-entry: patient takes in packs w/ "bridge" reful Net dication Discharge Instructions for Suboxone" Upon release, continue to take your medication as prescribed. If you need to continue taking medications, your lister pack will include a prescription for 5-day refil. Please call 877-826-5977 to leave the required information for your refill. You or your insurance will be responsible for pament for the refil.	
 Naloxone training & distribution A video "PSA" on overdose recognition & naloxone use – played at intake/ housing units daily Distribution of naloxone to individuals at highest risk of an overdose at time of release. PDP staff meet with all program participants to help them select a community outpatient treatment provider. Post-release appointment date scheduled for sentenced 	2. li 3. F i
 patients; referral to outpatient clinic for pre-sentenced. Option for adjunctive psychosocial treatment groups- participation not required. 	4. C cor

OBJECTIVES

escribe the implementation of buprenorphine armacotherapy in the Philadelphia Department of Prisons.

entify system and structural challenges, and policy commendations.

RESULTS

- Medicaid re-enrollment in jail successful- MA-eligible leave w/ coverage effective no later than date of release.
- Normalized for jail staff: OUD = chronic disease that warrants treatment; Treatment is in primary care scope.
- Harm reduction approach: if participants return to opioid use, their tolerance has been sustained +buprenorphine remains in their system for days. Risk of overdose theoretically is lower.
- **Engagement in care:** during pilot approx. 40% women were filling bridge RXs.
- In 2018 ~31% of patients started on buprenorphine in PDP and discharged in 2018 received community **Services** (from DBHIDS within 30 days)

~80% of eligible men participate 80% of participants are pre-sentence 50% of participants - discharged < 14 days

> **PILOT PROGRAM** at women's jail Feb. 5th- July 24th, 2018, women at RCF

25% appeared to have untreated OUD (1,9995 women entering 2/5/18 to 7/24/18, 507 scheduled/ 454 evaluated/ 297 treated who went out of custody/ 66 declined, or not assessed suitable, or stopped after starting, or administratively withdrawn)

20% engaged in buprenorphine maintenance (all women entering who received buprenorphine maintenance- entire length of incarceration.)

2.5% "diversion rate"10 out of 388 caught attempting to "cheek" or divert or misuse medication (and were administratively withdrawn due to misuse.)

Structural challenges

Pharmacy- ability to fill bridge script

Obstacles to authorization for refill RX: type of **buprenorphine** formulation (generic/brand tablet vs film) approved without a prior auth varies among (multiple) PA Medicaid plans. Also some jail prescribers lacked **Medicaid provider numbers**.

nsurance/cost

PA Medicaid software system

- a) Complexity/ uncertain MA re-activation times
- b) Unintended consequences: example- children's coverage terminated accidentally when incarcerated parent's coverage was suspended in system

Community treatment & justice system

mmunication: lacking case management or warm handoff" capacity- referrals not always seamless. Individual's release date/ time can't be predicted reliably. Challenges with patient history/records sharing w/treatment provider.

5. Data collection outcomes analysis: requires multiple cross-system partners /complex data sharing agreements needed.

Patient limits- newly certified physician, NP or PA only can have 30 patients at a time.

Corrections System Policy Innovation:

Demonstrates a harm reduction approach to treatment, allowing incarcerated, pre-sentenced individuals to maintain opioid tolerance and reduce their overdose risk on re-entry.

Next steps: Outcomes data analysis by city department of behavioral health, re: participant engagement in treatment, readmission to jail, and fatal overdose rates.

Summary: This first year jail buprenorphine program demonstrates successful engagement of eligible individuals, and ability to integrate OUD pharmacotherapy into large urban jail medical protocols, however regulatory barriers can be barriers to program capacity.

Policy implications: changes to federal opioid treatment regulations could reduce structural barriers.

former inmates. N Engl J Med. 2007;356(2):157-65 Moore, K., Roberts, W., Reid, H., Smith, K., Oberleitner, L., & Mckee, S. (2019). Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. Journal of Substance Abuse Treatment, 99, 32–43.

City of Philadelphia DOH, DBHIDS (March 2018) The Opioid Epidemic in Philadelphia Implementation of the Mayor's Task Force Recommendations (status report) Fox AD, Moore A, Binswanger IA, Kinner S. Deaths In Custody and Following Release. J Health Hum Serv Adm. 2019;41(4):45-84.

Vestal, C. (2018, August 4). New Momentum for Addiction Treatment Behind Bars.

Suet Lim, PhD, Research Director, Philadelphia DBHIDS; Latasha A. McMillan, Director of Operations Philadelphia, Corizon Health; Vandelyn Phillips, RN, BSN, CCHP, Regional V.P. Community Corrections, Corizon Health.

RESULTS

Structural Challenges

Regulatory barriers

• HHS, SAMHSA, CSAT--**DATA Waiver requirements**

An "emergency" request for a patient limit increase from 30 to 100 was needed after the physician w/275 patient limit left the system.

DEA: insufficient guidance on reg's re: patient panels /capacity

• Opioid Treatment Program (OTP) requirements

CONCLUSIONS

SELECTED CITATIONS

Binswanger IA, Stern MF, Deyo RA, et al. Release from prison--a high risk of death for

ACKNOWLEDGEMENTS